MD

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2006 for Pediatrix Medical Group, Inc., a provider of pediatric medical services. The filing is significant due to a comprehensive restatement of financial statements for prior periods (including 2005 and 2004) resulting from an Audit Committee review of historical stock option grant practices. The review identified backdating of options and accounting errors, leading to the recognition of additional non-cash stock-based compensation expense. The company also finalized a $25.1 million settlement regarding a federal Medicaid and TRICARE investigation during this period.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net patient service revenue increased 21.1% ($37.7 million) for the three months ended September 30, 2006, compared to the prior year. This was driven by a 15.6% increase in same-unit revenue due to pricing factors (new billing codes, managed care contracting) and volume growth, alongside $10.6 million from acquisitions.
• Expense Increases: Practice salaries and benefits rose 21.8% due to incentive compensation growth and costs associated with new physicians. General and administrative expenses increased 11.4%, partly due to professional fees related to the stock option review.
• Profitability: Operating income increased 27.2% to $56.5 million for the quarter. Net income rose 27.0% to $35.2 million. The effective tax rate increased to 38.9% from 37.5% in the prior year quarter.
• Restatement Impact: The 2005 comparative figures have been restated to reflect additional stock-based compensation expense. For the nine months ended September 30, 2005, net income was reduced by $1.2 million due to these adjustments.

Guidance, Outlook, Risks, and Contingencies

• Stock Option Restatement: The Audit Committee identified 56 backdated grants and 584 grants with erroneous measurement dates. The company recorded approximately $32.9 million in cumulative pre-tax expense adjustments through 2005. The SEC has commenced a formal investigation into these practices.
• Legal Settlements: The company paid $25.1 million to settle federal and state Medicaid/TRICARE investigations. This payment significantly impacted cash flow from operations in the nine-month period. The company entered into a five-year Corporate Integrity Agreement with the Office of Inspector General.
• Liquidity: The company maintains a $225 million Line of Credit with no outstanding principal balance as of September 30, 2006, though $25 million was utilized for letters of credit. Management believes current resources are sufficient for the next 12 months.
• Future Acquisitions: The company acquired seven practices in the first nine months of 2006 and four additional practices subsequent to the period end. A $100 million share repurchase program was authorized in August 2007.
• Risks: Risks include potential further restatements, litigation related to stock options, and the impact of government audits on billing practices. The company faces potential delisting from the NYSE if future filings are delayed due to regulatory disagreements.

Investor Verification Checklist

• Restatement Details: Verify the specific impact of the stock option restatement on the 2006 Form 10-K and subsequent quarterly reports.
• Regulatory Status: Monitor the status of the SEC investigation and any potential outcomes regarding the stock option practices.
• Compliance Obligations: Review the terms of the Corporate Integrity Agreement and the company's compliance reporting to the OIG.
• Cash Flow Sustainability: Assess the impact of the $25.1 million settlement payment on future liquidity and the ability to fund acquisitions without debt.
• Debt Covenants: Confirm continued compliance with the Line of Credit covenants, noting the extensions granted due to the restatement delays.